Literature DB >> 4048870

A human monoclonal IgG1 lambda anti-hepatitis B surface antibody. Production, properties, and applications.

E A Stricker, R F Tiebout, P N Lelie, W P Zeijlemaker.   

Abstract

Peripheral blood mononuclear cells from a donor with a high titre of anti-hepatitis B surface (HBs) antibodies were fused with a cell line that was positive for Epstein-Barr virus nuclear antigen and sensitive to hypoxanthine-aminopterine-thymidine. A cell line was established that produces a monoclonal IgG1 lambda anti-HBs antibody. Afterwards, it appeared that the anti-HBs antibody-producing cell line had arisen from Epstein-Barr virus transformation of the donor B cells. The cell line is capable of producing up to 60 micrograms/ml of the monoclonal antibody, which has a high avidity for HBs antigen (Ag) and recognizes both ad and ay subtypes. The antibody is useful as a reagent for the detection of HBsAg in human serum. Over 1000 patient sera have been tested with a conventional third-generation assay in parallel, and only a single discrepant serum was found.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4048870     DOI: 10.1111/j.1365-3083.1985.tb01889.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  4 in total

Review 1.  New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections.

Authors:  L Hammarström; C I Smith
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

2.  Requirements for growth of Epstein-Barr virus-transformed cells at low cell densities.

Authors:  R F Tiebout; R W Sauerwein; W G van der Meer; F van Boxtel-Oosterhof; W P Zeijlemaker
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

3.  Effective production of anti-tetanus toxoid and anti-HBsAg human monoclonal antibodies by serum-free culture of hybridomas.

Authors:  K Kitano; Y Ichimori; H Sawada; S Iwasa; S Sasai; K Tsukamoto
Journal:  Cytotechnology       Date:  1991-01       Impact factor: 2.058

Review 4.  Exploring the native human antibody repertoire to create antiviral therapeutics.

Authors:  S K Dessain; S P Adekar; J D Berry
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.